DNA倍体分析技术在宫颈癌早期患者筛查中的价值  

The Value of DNA Ploidy Analysis in the Screening of Patients with Early Cervical Cancer

作　　者：徐薇 范雪梅 赵群 孔祥[1,2] XU Wei;FAN Xuemei;ZHAO Qun;KONG Xiang(Department of Obstetrics and Gynecology,Xinghua People's Hospital Affiliated to Yangzhou University School of Medicine,Xinghua,Jiangsu Province,225700 China;Department of Obstetrics and Gynecology,Clinical School of Yangzhou University,Yangzhou,Jiangsu Province,225001 China)

机构地区：[1]扬州大学医学院附属兴化市人民医院妇产科,江苏兴化225700 [2]扬州大学临床医学院妇产科,江苏扬州225001

出　　处：《中外医疗》2021年第26期1-4,共4页China & Foreign Medical Treatment

摘　　要：目的研究宫颈癌早期患者筛查中运用DNA倍体分析技术的临床价值。方法便利选取2019年8月—2020年8月在该院门诊接受宫颈癌筛查的850例女性作为主要研究对象,所有研究对象均接受传统宫颈细胞学检测,同时均接受DNA倍体分析技术检测,对所有受检者的检测结果进行准确统计。对于检测结果为阳性的受检者,均予以宫颈活检,最终对所有受检者的检测结果进行回顾性分析。结果经传统宫颈细胞学检测,共有35例受检者的检测结果为阳性,阳性率为4.12%,经DNA倍体分析技术检测,共有78例受检者的检测结果是阳性,阳性率为9.18%,差异有统计学意义(χ^(2)=608.252,P<0.05)。35例经传统宫颈细胞学检测阳性受检者均接受阴道镜活检,检出阳性病例4例,阳性率为11.43%,78例经DNA倍体分析技术检测阳性受检者接受阴道镜活检,检出阳性52例,阳性率为66.67%,差异有统计学意义(χ^(2)=29.488,P<0.05)。结论在宫颈癌早期筛查中,DNA倍体分析技术有较好的临床应用价值,检出阳性率、特异度和灵敏度更高,可为疾病早期治疗方案的制定提供科学依据,及早发现及早予以治疗,最大程度上提高治疗的及时性和有效性,故值得进一步推广应用。Objective To study the clinical value of DNA ploidy analysis in the screening of early cervical cancer patients.Methods A total of 850 women who underwent cervical cancer screening in the outpatient department of the hospital from August 2019 to August 2020 were selected conveniently as the research subjects.All subjects received traditional cervical cytology and DNA ploidy analysis,and the test results of all subjects were accurately counted.Cervical biopsies were performed for positive subjects,and the results of all subjects were retrospectively analyzed.Results By traditional cytology,35 patients were positive,the positive rate was 4.12%.By DNA ploidy analysis,78 patients were positive,the positive rate was 9.18%,the difference was statistically significant(χ^(2)=608.252,P<0.05).Of the 35 patients who were positive by traditional cervical cytology underwent colposcopic biopsy,and 4 patients were positive,with a positive rate of 11.43%.Of the 78 patients who were positive by DNA ploidy analysis,52 patients were positive by colposcopic biopsy,with a positive rate of 66.67%.The difference was statistically significant(χ^(2)=29.488,P<0.05).Conclusion In the early screening of cervical cancer,DNA ploidy analysis technology has good clinical application value,with higher detection positive rate,specificity and sensitivity,which can provide scientific basis for the formulation of early treatment plans for the disease,and early detection and early treatment,to maximize the timeliness and effectiveness of treatment,so it is worthy of further promotion and application.

关 键 词：DNA倍体分析技术 宫颈癌 早期患者筛查 筛查价值 

分 类 号：R5[医药卫生—内科学]